Literature DB >> 25559992

The role of antimicrobials in the treatment of sepsis and critical illness-related bacterial infections: examination of the evidence.

Iain Keir1, Amy E Dickinson.   

Abstract

OBJECTIVE: To appraise the evidence behind the Surviving Sepsis Campaign Guidelines on antimicrobial therapy in sepsis and evaluate relevant literature in small animal veterinary critical care. DATA SOURCE: Electronic searches using MEDLINE and EMBASE databases. HUMAN DATA SYNTHESIS: Current recommendations are to administer appropriate antimicrobials within 1 hour of a diagnosis of severe sepsis or septic shock. Evidence is supportive of this recommendation in septic shock but the evidence is less compelling in milder forms of critical illness-related infections. It is unclear when the administration of appropriate antimicrobials is most beneficial and when it should be considered essential. Evidence supports shorter courses of antimicrobial therapy for many infections seen in the critical care unit with the biomarkers procalcitonin and C-reactive protein helpful in guiding the duration of therapy. VETERINARY DATA SYNTHESIS: Current evidence is lacking to support the use of early and aggressive use of antimicrobials in all patients with critical illness-related bacterial infections. Two studies failed to demonstrate improved survival in patients with pulmonary or abdominal infections administered appropriate vs inappropriate empirical antimicrobials. One study failed to show an improved survival when dogs with abdominal infections were administered antimicrobials within 1 hour vs 6 hours of diagnosis of infection. Information regarding ideal duration of antimicrobial therapy and use of biomarkers to guide therapy is currently lacking.
CONCLUSION: Clinicians should aim to administer early and appropriate antimicrobials; however, the impact this will have on patient outcome remains uncertain. The ability to administer early and appropriate antimicrobials may be considered a measure of the quality of medical practice rather than a prognostic indicator. © Veterinary Emergency and Critical Care Society 2015.

Entities:  

Keywords:  bacterial resistance; biomarkers; timing of therapy

Mesh:

Substances:

Year:  2015        PMID: 25559992     DOI: 10.1111/vec.12272

Source DB:  PubMed          Journal:  J Vet Emerg Crit Care (San Antonio)        ISSN: 1476-4431


  6 in total

1.  Prescribing patterns and comparison of culture versus empiric-based selection of meropenem in cats and dogs in a veterinary teaching hospital (2011-2018).

Authors:  Lillian M Cousto; J Scott Weese; Shane W Bateman
Journal:  Can Vet J       Date:  2020-03       Impact factor: 1.008

2.  Emergency Physician Compliance with Quality Indicators of Septic Shock and Severe Sepsis in Eastern Taiwanese Community Hospital.

Authors:  Chih-Chang Liu; Wan-Hua Annie Hsieh; Pei-Fang Lai; Sheng-Chuan Hu; Hui-Yi Huang; Zen Lang Bih
Journal:  J Acute Med       Date:  2017-12-01

3.  Agreement between Parallel Canine Blood and Urine Cultures: Is Urine Culture the Poor Man's Blood Culture?

Authors:  Nanelle R Barash; Adam J Birkenheuer; Shelly L Vaden; Megan E Jacob
Journal:  J Clin Microbiol       Date:  2018-08-27       Impact factor: 5.948

4.  An Agent-Based Model of a Hepatic Inflammatory Response to Salmonella: A Computational Study under a Large Set of Experimental Data.

Authors:  Zhenzhen Shi; Stephen K Chapes; David Ben-Arieh; Chih-Hang Wu
Journal:  PLoS One       Date:  2016-08-24       Impact factor: 3.240

5.  Procalcitonin-guided antibiotic therapy in critically ill adults: a meta-analysis.

Authors:  Tao Zhang; Yan Wang; Qianting Yang; Yalin Dong
Journal:  BMC Infect Dis       Date:  2017-07-24       Impact factor: 3.090

6.  Acute Ulcerative Enterocolitis With Severe Protein Loss Due to Mucosal Invasion With Enterococcus spp. in a Dog With Exocrine Pancreatic Insufficiency: A Case Report.

Authors:  Jennifer A Cartwright; Jorge Pérez-Accino; Clare Timothy; Kenneth W Simpson; Silke Salavati Schmitz
Journal:  Front Vet Sci       Date:  2020-10-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.